A neonatal mouse model of coxsackievirus A16 for vaccine evaluation

Journal of Virology

Volumn 86, Issue 22, 2012, Pages 11967-11976

  Qunying, Mao ^a   Yiping, Wang ^a   Rong, Gao ^b   Jie, Shao ^a   Xin, Yao ^a   Shuhui, Lang ^a   Chao, Wang ^c   Panyong, Mao ^b   Zhenglun, Liang ^a   Junzhi, Wang ^a  

^a NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

^b BEIJING 302 HOSPITAL   (China)

^c Hualan Biological Engineering Inc   (China)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS A; COXSACKIE VIRUS A16; COXSACKIE VIRUS INFECTION; DRUG EFFICACY; FEMALE; HEART MUSCLE; HINDLIMB PARALYSIS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LD 50; MOUSE; MUSCLE NECROSIS; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PARALYSIS; PRIORITY JOURNAL; SKELETAL MUSCLE; TROPISM; VACCINE PRODUCTION; WASTING SYNDROME;

ANIMALS; ANIMALS, NEWBORN; BRAIN; CERCOPITHECUS AETHIOPS; CULTURE MEDIA; DISEASE MODELS, ANIMAL; ENTEROVIRUS; FEMALE; HAND, FOOT AND MOUTH DISEASE; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED ICR; MODELS, GENETIC; PHYLOGENY; POLYMERASE CHAIN REACTION; TIME FACTORS; VACCINATION; VACCINES; VERO CELLS; VIRAL LOAD;

CAPRA HIRCUS; COXSACKIEVIRUS; MUS;

EID: 84869214165     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00902-12     Document Type: Article

References (56)

1. Bek EJ, et al. 2011. Formaldehyde-inactivated vaccine provokes crossprotective immunity in a mouse model of humanenterovirus 71 infection. Vaccine 29:4829-4838.
2. Bendig JW, Fleming DM. 1996. Epidemiological, virological, and clinical features of an epidemic of hand, foot, and mouth disease in England and Wales. Commun. Dis. Rep. CDR Rev. 6:R81-R86.
3. Chan YF, AbuBakar S. 2005. Human enterovirus 71 subgenotype B3 lacks coxsackievirus A16-like neurovirulence in mice infection. Virol. J. 2:74.
4. Chang LY, et al. 1999. Comparison of enterovirus 71 and coxsackievirus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Pediatr. Infect. Dis. J. 18:1092-1096.
5. Chen CS, et al. 2007. Retrograde axonal transport: a major transmission route of enterovirus 71 in mice. J. Virol. 81(17):8996-9003.
6. Chen CW, Lee YP, Wang YF, Yu CK. 2010. Formaldehyde-inactivated human enterovirus 71 vaccine is compatible for co-immunization with a commercial pentavalent vaccine. Vaccine 29:2772-2776.
7. Chiu CH, Chu C, He CC, Lin TY. 2006. Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes Infect. 8:1671-1678.
8. Chung YC, et al. 2008. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 26(15):1855-1862.
9. Dong C, et al. 2011. Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice andrhesus monkeys. Vaccine 29(37):6269-6275.
10. Dong C, et al. 2010. Optimized development of a candidate strain of inactivated EV71 vaccine and analysis of its immunogenicity in rhesus monkeys. Hum. Vaccine 6(12):1028-1037.
11. Gilbert GL. 1988. Outbreak of enterovirus 71 in Victoria, Australia with a high incidence of neurologic involvement.Pediatr. Infect. Dis. J. 7:484-488.
12. Gohd RS, Faigel HC. 1966. Hand, foot, and mouth disease resembling measles. A life-threatening disease: a case report. Pediatrics 37:644-648.
13. Goldberg MF, McAdams AJ. 1963. Myocarditis possibly due to coxsackie group A, type16, virus. J. Pediatr. 62:762-765.
14. Goto K, et al. 2009. Rhombencephalitis and coxsackievirus A16. Emerg. Infect. Dis. 15(10):1689-1691.
15. Ho M, et al. 1999. An epidemic of enterovirus 71 infection in Taiwan. N. Engl. J. Med. 341:929-935.
16. Hosoya M, et al. 2007. Genetic diversity of coxsackievirus A16 associated with hand, foot, and mouth disease epidemics in Japan from 1983 to 2003. J. Clin. Microbiol. 45(1):112-120.
17. Huang, WZ, et al. 2011. Genetic analysis and etiology study of hand-footmouth disease in surveillance hospitals of Hunan province during the period of 2008-2010. Practical Preventive Medicine 18(5):779-784.
18. HyypiÄ T, et al. 1993. Pathogenetic differences between coxsackie A and B virus infections in newborn mice. Virus Res. 27:71-78.
19. Iwai M, et al. 2009. Genetic changes of coxsackievirus A16 and enterovirus 71 isolated from hand, foot, and mouth disease patients in Toyama, Japan between 1981 and 2007. Jpn. J. Infect. Dis. 62:254-259.
20. Jia L, et al. 2011. Comparisons of epidemiological and clinical characteristics in children with hand-foot-mouth disease caused by enterovirus 71 and coxsackievirus A16. Chin. J. Contemp. Pediatr. 13(8):635-637.
21. Legay F, et al. 2007. Fatal coxsackievirus A16 pneumonitis in adults. Emerg. Infect. Dis. 13:1084-1086.
22. Li LL, et al. 2005. Genetic characteristics of human enterovirus 71 and coxsackievirus A16 circulating from 1999 to 2004 in Shenzhen, People's Republic of China. J. Clin. Microbiol. 43:3835-3839.
23. Li WA, et al. 2009. Epidemiology and control of hand, foot and mouth disease in Singapore, 2001-2007. Ann. Acad. Med. Singapore 38:106-112.
24. Li YP, et al. 2012. Safety and immunogenicity of a novel human enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, phase I clinical trial. Vaccine 30(22):3295-3303.
25. Lin TY, Twu SJ, Ho MS, Chang LY, Lee CY. 2003. Enterovirus 71 outbreaks, Taiwan: occurrence and recognition. Emerg. Infect. Dis. 9:291-293.
26. Liu ML, et al. 2005. Type I interferons protect mice against enterovirus 71 infection. J. Gen. Virol. 86:3263-3269.
27. Luo LF, et al. 2011. Severe hand foot and mouth disease (HFMD) suspected pathogen detection and epidemiological analysis. Chin. J. Health Lab. Technol. 21(4):971-972.
28. Luo XH, Zhang YM, Zhang JQ, He YY, Gao H. 2008. Etiological diagnosis and analysis of four outbreaks of hand-foot-mouth disease. Chin. Prev. Med. 9(12):1041-1043.
29. Mao QY, Yao X, Liang ZL. 2011. Animal infection models in the research of EV71 vaccine. Chin. J. Viral Dis. 1(3):222-226.
30. Mao QY, et al. 2010. Dynamic change of mother-source neutralizing antibodies against enterovirus 71 and coxsackievirus A16 in infants. Chin. Med. J. 123:1679-1684.
31. MartÍn J, Crossland G, Wood DJ, Minor PD. 2003. Characterization of formaldehyde-inactivated poliovirus preparations made from live attenuated strains. J. Gen. Virol. 84:1781-1788.
32. McMinn, PC. 2002. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol. Rev. 26:91-107.
33. Nagata N, et al. 2004. Differential localization of neurons susceptible to enterovirus 71 and poliovirus type 1 in the central nervous system of cynomolgus monkeys after intravenous inoculation. J. Gen. Virol. 85: 2981-2989.
34. Ogilvie MM, Tearne CF. 1980. Spontaneous abortion after hand, foot, and mouth disease caused by coxsackievirus A16. Br. Med. J. 281:1627-1628.
35. Ong KC, Devi S, Cardosa MJ, Wong KT. 2010. Formaldehyde inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J. Virol. 84(1):661-665.
36. Paoletti LC, Pinel J, Kennedy RC, Kasper DL. 2000. Maternal antibody transfer in baboons and mice vaccinated with a group B streptococcal polysaccharide conjugate. J. Infect. Dis. 181(2):653-658.
37. Podin Y, et al. 2006. Sentinel surveillance for human enterovirus 71 in Sarawak, Malaysia: lessons from the first 7 years. BMC Public Health 6:180.
38. Rabenau HF, Richter M, Doerr HW. 2010. Hand, foot and mouth disease: seroprevalence of coxsackie A16 and enterovirus71 in Germany. Med. Microbiol. Immunol. 199(1):45-51.
39. Reed LJ, Muench H. 1938. A simple method of estimating 50 percent end-points. Am. J. Hyg. 27:493-497.
40. Robinson CR, Doane FW, Rhodes AJ. 1958. Report of an outbreak of febrile illness with pharyngeal lesions and exanthem. Can. Med. Assoc. J. 79:615-621.
41. Shekhar K, et al. 2005. Deaths in children during an outbreak of hand, foot and mouth disease in peninsular Malaysia- clinical and pathological characteristics. Med. J. Malaysia 60(3):297-304.
42. Shi WP, et al. 2010. Epidemiological survey of three outbreaks of CoxA16-induced hand, foot and mouth disease in kindergartens. Dis. Surveill. 25(1):22-24.
43. Sickles GM, Mutterer M, Feorino P, Plager H. 1955. Recently classified types of coxsackievirus, group A. Behavior intissue culture. Proc. Soc. Exp. Biol. Med. 90:529-531.
44. Urquhart GED. 1984. A survey of coxsackie A16 virus antibodies in human
45. Wang CY, Li LF, Wu MH, Lee CY, Huang LM. 2004. Fatal coxsackievirus A16 infection. Pediatr. Infect. Dis. J. 23:275-276.
46. Wright HT, Landing BH, Lennette EH, Mcallister RM. 1963. Fatal infection in an infant associated with coxsackie virus group A, type 16. N. Engl. J. Med. 9:1041-1044.
47. Wu CN, et al. 2001. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20:895-904.
48. Wu PC, et al. 2010. An outbreak of coxsackievirus A16 infection: comparison with other enteroviruses in a preschool in Taipei. J. Microbiol. Immunol. Infect. 43(4):271-277.
49. Wu TC, et al. 2007. Immunity to avirulent enterovirus 71 and coxsackie A16 virus protects against enterovirus 71 infection in mice. J. Virol. 81(19):10310-12315.
50. Yang WS. 2011. Clinical characteristic analysis of 104 cases of children severe hand, foot and mouth disease. Chongqing Med. 40(17):1722-1727.
51. Yao X, et al. 2010. Genetic characteristics of coxsackievirus A16 complete genome isolated in Beijing, 2008. Chin. J. Epidemiol. 31(12):1437-1438.
52. Ye RX, Zhang YL, Pan KN, Tong YX. 2011. Significance of enterovirus 71 and coxsackievirus 16 pathogens detection in preventing epidemics of hand, foot and mouth disease. Chin. J. Nosocomiol. 21(7):1295-1296.
53. Yu CK, et al. 2000. Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J. Biomed. Sci. 7:523-528.
54. Zhang W, et al. 2011. Severe hand, foot, and mouth disease caused by mixed infection of enterovirus 71 and coxsackie A16: report of 6 cases. Chin. Gen. Practice 14(10):3341-3346.
55. Zhang YJ, Bai J, Huang XL. 2010. Clinical analysis of 54 cases of hand, foot and mouth disease with central nervous system damage. Chin. J. Crit. Care Med. 30(12):1090-1092.
56. Zhu Z, et al. 2010. Retrospective seroepidemiology indicated that human enterovirus 71 and coxsackievirus A16 circulated wildly in central and southern China before large-scale outbreaks from 2008. Virol. J. 7:300.